Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity.
paper
Cited
Public
Unavailable
- Authors
- Oscarson, Mikael; McLellan, Roman A; Asp, Vendela; Ledesma, MariCarmen; Bernal Ruiz, Maria Luisa; Sinues, Blanca; Rautio, Arja; Ingelman-Sundberg, Magnus
- Year
- 2002
- Journal
- Human mutation
- PMID
- 12325023
- DOI
- 10.1002/humu.10126
The human CYP2A6 enzyme metabolizes certain drugs and pre-carcinogens and appears to be the most important enzyme for nicotine metabolism. At present, more than 10 different allelic variants are known that cause abolished or decreased enzyme activity. Genetic polymorphism in this gene might be of particular importance for an individual's need for nicotine and for susceptibility to lung and/or liver cancer. We have identified a new CYP2A6 allele (CYP2A6*12) which carries an unequal crossover between the CYP2A6 and CYP2A7 genes in intron 2. This results in a hybrid allele where the 5' regulatory region and exons 1-2 are of CYP2A7 origin and exons 3-9 are of CYP2A6 origin, resulting in 10 amino acid substitutions compared to the CYP2A6(*)1 allele. Phenotyping with the CYP2A6 substrate coumarin indicates that it causes reduced CYP2A6 activity in'vivo. Furthermore, when expressed in mammalian COS-1 cells, the enzyme variant catalyzed 7-hydroxylation of coumarin at a rate approximately 60% of that of the wild-type enzyme. The CYP2A6(*)12 allele was present at an allele frequency of 2.2% among Spaniards, but was absent in Chinese.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Fine-mapping the CYP2A6 regional association with nicotine metabolism among African American smokers. | Pouget JG et al. | — | 2025 | → |
| Novel CYP2A7/CYP2A6 germline hybrids associated with mutation burden in lung cancer revealed by whole-genome long-read sequencing. | Ohnami S et al. | — | 2025 | → |
| Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism. | Guengerich FP | — | 2024 | → |
| Genotyping, characterization, and imputation of known and novel CYP2A6 structural variants using SNP array data. | Langlois AWR et al. | — | 2023 | → |
| Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers. | Perez-Paramo YX et al. | — | 2023 | → |
| Pharmacogenetic Variation in Neanderthals and Denisovans and Implications for Human Health and Response to Medications. | Wroblewski TH et al. | — | 2023 | → |
| Human Orphan Cytochromes P450: An Update. | Molina-Ortiz D et al. | — | 2022 | → |
| Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. | Perez-Paramo YX et al. | — | 2021 | → |
| Genetic variants in CYP2A6 and UGT1A9 genes associated with urinary nicotine metabolites in young Mexican smokers. | Borrego-Soto G et al. | — | 2020 | → |
| Use of a non-hepatic cell line highlights limitations associated with cell-based assessment of metabolically induced toxicity. | Weyers C et al. | — | 2020 | → |
| Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences. | Lee SB et al. | — | 2019 | → |
| Cancer Hazard Identification Integrating Human Variability: The Case of Coumarin. | Hsieh CJ et al. | — | 2019 | → |
| Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. | Borrie AE et al. | — | 2018 | → |
| Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. | López-Flores LA et al. | — | 2017 | → |
| Variation in CYP2A6 Activity and Personalized Medicine. | Tanner JA et al. | — | 2017 | → |
| CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms. | Wassenaar CA et al. | — | 2016 | → |
| A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism. | Loukola A et al. | — | 2015 | → |
| Cohort Profile: The Nicotine Dependence in Teens (NDIT) Study. | O'Loughlin J et al. | — | 2015 | → |
| Advances in molecular modeling of human cytochrome P450 polymorphism. | Martiny VY et al. | — | 2013 | → |
| The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. | Zhu AZ et al. | — | 2013 | → |
| CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. | Binnington MJ et al. | — | 2012 | → |
| Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: comparison with other populations. | Soriano A et al. | — | 2011 | → |
| Genetic vulnerability and susceptibility to substance dependence. | Bierut LJ | — | 2011 | → |
| Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology. | Guengerich FP et al. | — | 2011 | → |
| The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. | Bloom J et al. | — | 2011 | → |
| Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. | Al Koudsi N et al. | — | 2010 | → |
| Pharmacogenetics of smoking cessation therapy. | Kortmann GL et al. | — | 2010 | → |
| In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. | di Iulio J et al. | — | 2009 | → |
| Molecular genetics of nicotine metabolism. | Mwenifumbo JC et al. | — | 2009 | → |
| Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population. | Wang HH et al. | — | 2009 | → |
| Polymorphism of human cytochrome P450 enzymes and its clinical impact. | Zhou SF et al. | — | 2009 | → |
| Rapid detection of the CYP2A6*12 hybrid allele by Pyrosequencing technology. | Koontz DA et al. | — | 2009 | → |
| CYP2A6 polymorphisms and risk for tobacco-related cancers. | Rossini A et al. | — | 2008 | → |
| Smoking risk and the likelihood of quitting among African-American female light and heavy smokers. | Fernander A et al. | — | 2008 | → |
| A novel duplication type of CYP2A6 gene in African-American population. | Fukami T et al. | — | 2007 | → |
| Characterization of orphan human cytochromes P450. | Stark K et al. | — | 2007 | → |
| CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients? | Farinola N et al. | — | 2007 | → |
| Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. | Mwenifumbo JC et al. | — | 2007 | → |
| Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. | Mwenifumbo JC et al. | — | 2007 | → |
| Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. | Rotger M et al. | — | 2007 | → |
| 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. | Wang J et al. | — | 2006 | → |
| CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. | Fukami T et al. | — | 2006 | → |
| Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. | Malaiyandi V et al. | — | 2006 | → |
| In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. | Peamkrasatam S et al. | — | 2006 | → |
| A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. | Fukami T et al. | — | 2005 | → |
| Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. | Fukami T et al. | — | 2005 | → |
| CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. | Vasconcelos GM et al. | — | 2005 | → |
| CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents. | Huang S et al. | — | 2005 | → |
| Function of human cytochrome P450s: characterization of the orphans. | Guengerich FP et al. | — | 2005 | → |
| High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana. | Gyamfi MA et al. | — | 2005 | → |
| Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. | Malaiyandi V et al. | — | 2005 | → |
| Integrative epidemiology: from risk assessment to outcome prediction. | Spitz MR et al. | — | 2005 | → |
| Metabolism and disposition kinetics of nicotine. | Hukkanen J et al. | — | 2005 | → |
| Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. | Swan GE et al. | — | 2005 | → |
| Three haplotypes associated with CYP2A6 phenotypes in Caucasians. | Haberl M et al. | — | 2005 | → |
| A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. | Pitarque M et al. | — | 2004 | → |
| Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. | Nelson DR et al. | — | 2004 | → |
| Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. | Schoedel KA et al. | — | 2004 | → |
| Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. | O'Loughlin J et al. | — | 2004 | → |
| Novel human CYP2A6 alleles confound gene deletion analysis. | Nakajima M et al. | — | 2004 | → |
| Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). | von Richter O et al. | — | 2004 | → |
| Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population. | Saito S et al. | — | 2003 | → |